Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective-Reference-Cited by-同舟云学术

Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective

Published:2022 Issue:6 Volume:33 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Li Ning¹^ORCID,Liu Qi²^ORCID,Tian Yu²^ORCID,Wu Lingying¹^ORCID

Affiliation:

1. Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

2. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Shanghai, China.

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2022.33.e86

Reference35 articles.

1. International Agency for Research on Cancer (IARC), World Health Organization. Cancer today [Internet]. Geneva. World Health Organization. 2020. cited 2022 Oct 10. Available from: https://gco.iarc.fr/today/home

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Protein Panel of Serum-Derived Small Extracellular Vesicles for the Screening and Diagnosis of Epithelial Ovarian Cancer

4. Management of relapsed ovarian cancer: a review

5. Epithelial ovarian cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

2. Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers;Cancer Chemotherapy and Pharmacology;2024-05-04

3. Clinical characterization and genomic landscape of gynecological cancers among patients attending a Chinese hospital;Frontiers in Oncology;2023-03-30

4. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects;Investigational New Drugs;2023-02-17

5. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3;Journal of Gynecologic Oncology;2023